NY-AQARA
Aqara, a leading provider of smart home solutions, today announced the availability of the Motion and Light Sensor P2, its new generation motion sensor built upon the Thread protocol and the industry-unifying Matter standard. The native Matter connectivity offers unparalleled compatibility across smart home platforms including Amazon Alexa, Apple Home, Google Home, and Samsung SmartThings1. With Matter's local networking capabilities, the P2 sensor ensures enhanced responsiveness and reliability.
“In the rapidly expanding global market for Passive Infrared (PIR) sensors, Aqara has achieved remarkable success, distributing over 100,000 units last year,” states Cathy You, Aqara Senior Vice President, Global Business and Strategy. “The launch of the Motion and Light Sensor P2, which combines our renowned sensor technology with the latest in connectivity protocols and standards, encapsulates our forward-thinking approach and our commitment to delivering smart home solutions that are ready for tomorrow's advancement.”
The Motion and Light Sensor P2 integrates an ultra-wide angle PIR motion sensor with a standalone illumination sensor, providing precise detection up to 7 meters (ca. 23 feet) and 170° horizontally2. This facilitates a range of use scenarios from automated lighting and security enhancement to climate control. The sensor also measures light intensity independently of motion detection3, enabling sophisticated lighting and window covering control for optimal comfort and energy efficiency. Engineered for longevity, the Motion and Light Sensor P2 boasts a robust battery life of up to two years, ensuring dependable operation with minimal maintenance.
As a Thread-enabled device, the Motion and Light Sensor P2 connects to any Matter controller with Thread Border Router functionality, and allows use across multiple compatible platforms thanks to Matter's multi-admin feature. Furthermore, the sensor offers a few Aqara Home exclusive features such as customizable sensitivity and detection timeout settings for tailored performance4. Users can fine-tune both parameters through the Aqara Home app, which requires Aqara's own Thread-enabled Matter controller, for example the upcoming Hub M3.
As part of Aqara’s expanding Thread-enabled product line, the Motion and Light Sensor P2 exemplifies the Company’s dedication to elevating smart home experiences through enhanced interoperability and simplicity. Additional Thread devices from Aqara are expected in the coming months, including the aforementioned Hub M3 and the retrofit home access solution Smart Lock U200.
The Motion and Light Sensor P2 is now available in Aqara’s Amazon brand stores in North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide5.
For more information on this sensor, please visit our website.
1. A Matter controller with Thread Border Router functionality is required for the connection to the corresponding Matter-enabled system.
2. Based on the internal lab test, measured under the ambient temperature of 25 °C (ca. 77 °F) and high sensitivity level.
3. Illumination sensing functionality is not available on Alexa at the time of launch.
4. By default, the sensor is set to medium sensitivity and a 30-second detection timeout.
5. Product availability may vary by retail channel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409809799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
